Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Poor prognosis is ZAP70’ed into focus in CLL

Adam J. Linley, Joseph R. Slupsky

Blood (2021) 137 (26): 3586–3587.

https://doi.org/10.1182/blood.2021011270

Published: 2021

Journal Articles

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

Elizabeth M. Muhowski, Amy M. Lehman, M.A.S, Sean D. Reiff, PhD, Janani Ravikrishnan, Rose Mantel, Shrilekha Misra, Michael Niesman, PhD, Kai Zhang, MD, James S. Blachly, MD, Deepa Sampath, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 2077.

https://doi.org/10.1182/blood-2019-128871

Published: 2019

Journal Articles

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Jeffrey S. Miller, MD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Ge Moyar, Bruce R. Blazar, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD, Frank Cichocki, PhD

Blood (2019) 134 (Supplement_1): 1933.

https://doi.org/10.1182/blood-2019-124961

Published: 2019

Journal Articles

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

Gonzalo Blanco, PhD, Anna Puiggros, PhD, Barbara Sherry, PhD, Lara Nonell, Eulalia Puigdecanet, Pui Yan Chiu, Yasmine Kieso, MSCR, Gerardo Ferrer, PhD, Magdalena Arnal, María Rodríguez-Rivera, Eva Gimeno, MD PhD, Eugenia Abella, Kanti R Rai, MD, Pau Abrisqueta, MD PhD, Xavier Calvo, MD PhD, Francesc Bosch, MD PhD, Ana Ferrer, MD PhD, Nicholas Chiorazzi, MD, Blanca Espinet, PhD

Blood (2019) 134 (Supplement_1): 3027.

https://doi.org/10.1182/blood-2019-122038

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 3041.

https://doi.org/10.1182/blood-2019-126286

Published: 2019

Journal Articles

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

Marlie H Fisher, Greg Kirkpatrick, PhD, Courtney L Jones, PhD, Brett M. Stevens, PhD, Michael Callaghan, MD, Eric Pietras, PhD, Kenneth L. Jones, PhD, Christopher C. Porter, MD, Jorge Di Paola, MD

Blood (2019) 134 (Supplement_1): 2316.

https://doi.org/10.1182/blood-2019-132032

Published: 2019

Journal Articles

p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development

Rasoul Pourebrahimabadi, MD PhD, Zoe Alaniz, Lauren B Ostermann, Hung Alex Luong, Rafael Heinz Montoya, Peter P. Ruvolo, PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Carlos E. Bueso-Ramos, MD PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 523.

https://doi.org/10.1182/blood-2019-127245

Published: 2019

Journal Articles

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Hong Yin, MD PhD, Yi Huo, PhD, Zhen Sheng, PhD, Chi-Ming Li, PhD, Daniel C Ellwanger, PhD, Daniel Lu, PhD, Oliver Homann, PhD, Songli Wang, MD PhD, Ruibao Ren, MD PhD

Blood (2019) 134 (Supplement_1): 3886.

https://doi.org/10.1182/blood-2019-124636

Published: 2019

Journal Articles

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

Mariela Sivina, Gordon Duncan, MSc, Takashi Sakamoto, MD PhD, Ekaterina Kim, MS, Alicia Vaca, PhD, Elena Maria Hartmann, MD, Michael J Keating, MBBS, Alessandra Ferrajoli, MD, William G. Wierda, MD PhD, Tak Mak, PhD DSc, Andreas Rosenwald, MD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 5448.

https://doi.org/10.1182/blood-2019-125716

Published: 2019

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

https://doi.org/10.1182/blood-2019-130784

Published: 2019

Journal Articles

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

Lei Fan, MD PhD, Chao Wang, Zhiqiang Wang, Xian Zhang, Lei Cao, Yi Miao, MD PhD, Xinyi Du, Wei Xu, MD PhD, Jianyong Li, MD

Blood (2019) 134 (Supplement_1): 5306.

https://doi.org/10.1182/blood-2019-129469

Published: 2019

Journal Articles

The Role of Interferon, Inflammation and Infection in Aplastic Anemia

Katherine C. MacNamara, PhD

Blood (2019) 134 (Supplement_1): SCI-34.

https://doi.org/10.1182/blood-2019-121036

Published: 2019

Journal Articles

Vδ1+ T Cells: Adoptive Cell Therapy for the Treatment of Haematological Malignancies in Allogeneic Settings

André Simoes, PhD, Joanna Kawalkowska, PhD, Timothy Recaldin, PhD, Daniel Foxler, PhD, Oliver Nussbaumer, PhD, Michael Koslowski, MD

Blood (2019) 134 (Supplement_1): 3221.

https://doi.org/10.1182/blood-2019-125688

Published: 2019

Journal Articles

Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias

Annelies J. Van Vuren, MD, Michele F. Eisenga, MD PhD, Stephanie van Straaten, MD PhD, Andreas Glenthøj, MD PhD, Carlo A.J.M. Gaillard, MD PhD, Stephan J.L. Bakker, MD PhD, Martin H. de Borst, MD PhD, Richard van Wijk, PhD, Eduard J. van Beers, MD PhD

Blood (2019) 134 (Supplement_1): 4793.

https://doi.org/10.1182/blood-2019-124074

Published: 2019

Journal Articles

Dasatinib Effect on NK Cells and Anti-Tumor Immunity

Mieszko Lachota, Marta Siernicka, MSc, Zofia Pilch, PhD, Agnieszka Graczyk-Jarzynka, PhD, Magdalena Winiarska, PhD

Blood (2018) 132 (Supplement 1): 3004.

https://doi.org/10.1182/blood-2018-99-111280

Published: 2018

Journal Articles

Patient's T Cell Functionality Determines Blinatumomab-Mediated Killing of B-ALL Leukemia Cells

Hong Yin, MD PhD, Xian Jia, MS, Xiaojie Guo, PhD, Yong Zhou, MD, Manman Deng, MD, Jian Li, MS, Yan Qiu, MS, Limin Lu, PhD, En-Tzu Tang, PhD, Xiaolei Chen, MS, Guo Fu, PhD, Mingqiang Zhang, PhD, Bing Xu, MD PhD, Ruibao Ren, MD PhD, Zhiqiang Du, MD PhD

Blood (2018) 132 (Supplement 1): 4079.

https://doi.org/10.1182/blood-2018-99-114503

Published: 2018

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Stim1 Deletion Synthetically Rescues Ezh2-Null Effector T Cells and Alloimmunity

Ying Wang, PhD, Shan He, PhD, Yongnian Liu, Robert Hooper, PhD, Hongshuang Yu, Yuanyuan Tian, Hongxing Sun, PhD, Ran Reshef, MD MSc, Elizabeth O. Hexner, MD MS, Jonathan Soboloff, Yi Zhang, MD

Blood (2018) 132 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2018-99-118720

Published: 2018

Journal Articles

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Yun Chen, PhD, Michael Y. Choi, MD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Emanuela M. Ghia, PhD, Elsa Sanchez-Lopez, PhD, George F. Widhopf II, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2018-99-111996

Published: 2018

NARROW

Poor prognosis is ZAP70’ed into focus in CLL

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia

iPSC-Derived NK Cells Synergize with T Cells and Anti-PD-1 Antibody to Mediate Durable Anti-Tumor Responses In Vivo

Gene Expression and Cytokine Analyses Identify Markers of Progression from CLL-like Monoclonal B-Cell Lymphocytosis to Chronic Lymphocytic Leukemia

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes

p53 Mediated Bone Marrow Mesenchymal Stem Cell Expansion Supports Acute Myeloid Leukemia Development

Blinatumomab-Induced T Cell Activation at Single Cell Transcriptome Resolution

Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

SHC014748M, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Pre-Clinical Antitumor Activity in B Cell Lymphomas and CLL

The Role of Interferon, Inflammation and Infection in Aplastic Anemia

Vδ1+ T Cells: Adoptive Cell Therapy for the Treatment of Haematological Malignancies in Allogeneic Settings

Erythropoietin Is Associated with a Decline in the iFGF23/cFGF23 Ratio in Patients with Various Hereditary Hemolytic Anemias

Dasatinib Effect on NK Cells and Anti-Tumor Immunity

Patient's T Cell Functionality Determines Blinatumomab-Mediated Killing of B-ALL Leukemia Cells

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Stim1 Deletion Synthetically Rescues Ezh2-Null Effector T Cells and Alloimmunity

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only